Comparative Pharmacology
Head-to-head clinical analysis: CHLORPHENIRAMINE MALEATE versus DISOMER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CHLORPHENIRAMINE MALEATE versus DISOMER.
CHLORPHENIRAMINE MALEATE vs DISOMER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
H1 receptor antagonist; competitively blocks histamine at H1 receptors, preventing histamine-mediated symptoms such as vasodilation, increased capillary permeability, and smooth muscle contraction.
Selective dopamine D2 receptor antagonist; also blocks alpha-1 adrenergic, histamine H1, and muscarinic M1 receptors.
4 mg orally every 4-6 hours, not to exceed 24 mg per day; or 10-20 mg intramuscularly or intravenously as a single dose, not to exceed 40 mg per day.
Adults: 1 mg orally once daily.
None Documented
None Documented
Terminal elimination half-life: 12-15 hours (prolonged in hepatic impairment).
Clinical Note
moderateDexchlorpheniramine maleate + Haloperidol
"The metabolism of Haloperidol can be decreased when combined with Dexchlorpheniramine maleate."
Clinical Note
moderateDexchlorpheniramine maleate + Sulfisoxazole
"The metabolism of Sulfisoxazole can be decreased when combined with Dexchlorpheniramine maleate."
Clinical Note
moderateDexchlorpheniramine maleate + Erythromycin
"The metabolism of Erythromycin can be decreased when combined with Dexchlorpheniramine maleate."
Clinical Note
moderate12–15 hours in adults with normal renal function; prolonged to 30–40 hours in severe renal impairment (CrCl <30 mL/min).
Renal: ~50% as metabolites; Fecal: negligible; Biliary: minor.
Renal: 80% as unchanged drug; biliary/fecal: 15% as metabolites; <5% unchanged in feces.
Category C
Category C
Antihistamine
Antihistamine
Dexchlorpheniramine maleate + Cyclosporine
"The metabolism of Cyclosporine can be decreased when combined with Dexchlorpheniramine maleate."